For instance, in the SWOG S1513 trial, this phase II study of second-line FOLFIRI with veliparib was stratified into three different HRD pancreatic cancer groups: (1) BRCA1/2; (2) non-BRCA core HRD including ATM, ATR, PALB2, CDK12, RAD51C/D, BARD1, BRIP1 alterations; and (3) non-core HRD including BLM, FANC, CHK1, CHK2, SLX4, ERCC, RIF1 alterations9. This evidence concerns the gene BRIP1 and familial pancreatic carcinoma.